The Readout Loud
STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
Mentioned books
Jul 26, 2018 • 25min
Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data
What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?
Jul 19, 2018 • 26min
Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season
Can drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR? Listen, and all will be explained.
Jul 12, 2018 • 25min
Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines'
Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug actually works?
Jul 5, 2018 • 20min
Episode 18: Biotech's six-month review, how to become a day trader and soul-searching analysts
Adam and Damian recap the past six months in biotech. Investor and philanthropist, Sheff Station, stops by and gives tips on how to become a day trader, and analysts questioning their very existence.
Jun 28, 2018 • 23min
Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China
How did the FDA become so friendly to the drug industry? The thorny issue of using 23andMe to unite families separated at the border, and Rebecca explains how drugs are priced in China.
Jun 21, 2018 • 26min
Episode 16: Sarepta's big week, Theranos' legal woes and parsing AI hype
Is Sarepta Therapeutics worth $10 billion? Will Theranos' Elizabeth Holmes go behind bars? And how does AI fit into biotech?
Jun 14, 2018 • 24min
Episode 15: Problematic parties, Nitpicking NASH, and an opioid documentary from STAT
The problem with the topless dancers at PABNAB. Are investors overestimating the market for fatty liver drugs? And how many lives do biotech entrepreneurs get?
Jun 7, 2018 • 27min
Episode 14: Twitter vitriol, biotech jargon, and the plight of the CEO
Why is Twitter so mean to Axovant? Adam teaches a crash course on biostatistics. And will sci-fi gene and cell therapies ever go mainstream.
May 31, 2018 • 23min
Episode 13: Spending millions on fatty liver disease. Overhyped cancer drugs. Who goes to BIO?
Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?
May 24, 2018 • 28min
Episode 12: Ebola should worry you, again; 23andMe's World Cup whoops; Don't drink sunscreen
How worried should you be about Ebola? Can the government lower drug prices without hurting the drug industry? And is socceromics a thing? Listen this week to find out.
